AZmed vs Qure.ai
Updated October 16, 2026
Hospitals and imaging centers adding AI to X-ray reading often compare AZmed and Qure.ai. AZmed's Rayvolve works as a second reader for fractures and chest findings on X-ray, while Qure.ai triages critical findings on chest X-ray, CT, and emergency studies so they move up the worklist. Centers focused on trauma X-rays and centers wanting broad triage tend to choose differently.
Our analysts compared AZmed and Qure.ai on what each reads, how it is used, results, product breadth, rollout, and pricing, using the HIR review of each company and both vendors' newsrooms. In the following sections, we compare the tools, describe the imaging center each suits, and list each company's latest clearances.
AZmed vs Qure.ai at a glance, October 2026
| What buyers weigh | AZmed | Qure.ai |
|---|---|---|
| Pricing model | Imaging AI software, sold as a subscription or priced per study, with quotes for each customer. | Radiology AI licenses per study or for the whole organization, quoted by imaging type and volume. |
| What drives cost | Scan volume, which modules you add (fracture, chest, measurements), and the number of sites. | Study volume by imaging type, which algorithms you buy, regions covered, and support. |
| What it reads | X-ray only, for fractures, chest findings, and measurements. | Chest X-ray, CT, and other emergency studies. Clear edge |
| How it is used | A second reader that marks findings for the radiologist. | Moves critical cases up the worklist inside the imaging system and supports the read. |
| Results | Scores 7.0 on detection and workflow outcomes. | Scores 7.5 on triage and detection outcomes. Higher score |
| Product breadth | Scores 7.0 for its X-ray product. | Scores 7.4 for the breadth of its radiology AI. Higher score |
| Getting live | Scores 6.7, and it needs a radiologist to lead the rollout and image system integration. | Scores 7.1, and it needs integration with the image archive and worklist. Higher score |
| Time to full value | About 3 to 6 months | About 4 to 8 months |
| What you need first | A named radiologist to lead it. | An owner for the PACS and RIS connection. |
| Deal-breaker | You only want an AI scribe. | You have no imaging volume. |
| Pricing clarity score | 6.6 | 7.0 Clearer pricing |
| HIR overall score | 6.9, Conditional. | 7.4, Recommend. Higher score |
| Best for | Hospitals and imaging centers that want X-ray fracture and chest AI as a second reader. | Hospitals and imaging networks that need AI triage for chest X-ray, CT, and emergency findings. |
| Not a fit for | Clinics without radiology ownership to act on AI flags. | Clinics with no imaging volume and no PACS integration path. |
Which fits which buyer
Decide whether you want a second reader or a triage tool.
Choose AZmed if
- Fracture and chest X-ray reads make up most of your volume.
- You want AI to mark findings as a second reader.
- You serve pediatric patients as well as adults.
Choose Qure.ai if
- You want triage across chest X-ray, CT, and emergency studies.
- Critical cases should jump the worklist automatically.
- You want a vendor with many FDA-cleared indications.
Verdict
Qure.ai scores higher and is the broader platform for hospitals that want triage across modalities. AZmed suits imaging centers that mainly need a fracture and chest X-ray second reader.
Neither replaces the radiologist.
Where the two tools are headed in 2027 and beyond
AZmed: AZmed received its sixth FDA clearance, expanding its chest X-ray product, on September 15, 2026.
Qure.ai: Qure.ai announced on February 26, 2026 that its FDA-cleared indications had grown to twenty-six with the clearance of qXR-Detect.
Ask both for sensitivity data on your own patient population.
Methodology
Each row comes from the HIR reviews of AZmed and Qure.ai, scored under the HIR method, and from each vendor's public pricing where it exists. Any published price for AZmed or Qure.ai was checked on that vendor's own site on October 16, 2026.
A green check marks a clear edge for AZmed or Qure.ai only where their review scores differ by at least 0.3 points or the two reviews show a plain difference. Rows with nothing published for either AZmed or Qure.ai are left out, and time to full value for each adds up the rollout stages in its review.
Sources
- HIR review of AZmed and HIR review of Qure.ai
- AZmed website
- Qure.ai website
- AZmed sixth FDA clearance, September 15, 2026
- Qure.ai indications reach twenty-six, February 26, 2026